NANO Nuclear Energy (NNE) Prices 2.56M Share IPO at $4/sh

NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear”) today announced the pricing of its initial public offering of 2,562,500 shares of its common stock at a price to the public of $4.00 per share, less underwriting discounts and commissions. The sole book-running manager of the offering will have a 30-day option to purchase up to an additional 384,375 shares of common stock from NANO Nuclear at the initial public offering price, less underwriting discounts and commissions.

NANO Nuclear’s common stock has been approved for listing and is expected to begin trading on the Nasdaq Capital Market under the symbol “NNE” on Wednesday, May 8, 2024.

The offering is expected to close on May 10, 2024, subject to customary closing conditions.

The gross proceeds to NANO Nuclear from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $10,250,000 million. NANO Nuclear intends to use the net proceeds from this offering to continue the research and development of its proprietary micro nuclear reactor designs, ‘ZEUS’ and ‘ODIN’, advancing its exclusive licensed technology to transport commercial quantities of High-Assay, Low-Enriched Uranium (HALEU) fuel needed for the future of the advanced nuclear industry, development of a U.S. domestic source of HALEU fuel fabrication for NANO Nuclear’s own microreactors and the broader advanced nuclear reactor industry as well as general corporate purposes and working capital.

The Benchmark Company, LLC is acting as sole book-running manager for the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, and became effective on May 6, 2024. The proposed offering will be made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from The Benchmark Company, LLC, 150 East 58th St., 17th Floor, New York, NY 10155, by telephone: (212) 312-6700, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Entrata (ENT) files for proposed IPO
• Electra Therapeutics files for proposed IPO
• Chinese AI chipmaker Enflame aims to raise $908 million after setting Shanghai IPO price